BridgeBio Pharma (BBIO) CAO logs small share sale and tax withholding

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported two transactions in the company’s common stock. On February 17, 2026, Apuli executed an open-market sale of 510 shares at $74.31 per share under a pre-arranged Rule 10b5-1 trading plan. On February 16, 2026, 4,349 shares were withheld to cover taxes tied to the vesting of 8,377 restricted stock units. After these transactions, Apuli directly owned 123,945 shares, which include the 510 shares acquired on February 13, 2026 through the company’s employee stock purchase plan.

Insider Trade Summary

Net Seller: 510 shares ($37,898)

Net Sell 2 txns

Insider Apuli Maricel

Role Chief Accounting Officer

Sold 510 shs ($38K)

Type	Security	Shares	Price	Value
Sale	Common Stock	510	$74.31	$38K
Tax Withholding	Common Stock	4,349	$75.25	$327K

Holdings After Transaction: Common Stock — 123,945 shares (Direct)

Footnotes (1)

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 8,377 shares of Common Stock underlying the Reporting Person's RSUs. Includes 510 shares of the Issuer's Common Stock acquired by the Reporting Person on February 13, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/16/2026		F		4,349(1)	D	$75.25	124,455(2)	D
Common Stock	02/17/2026		S(3)		510	D	$74.31	123,945	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 8,377 shares of Common Stock underlying the Reporting Person's RSUs.

2. Includes 510 shares of the Issuer's Common Stock acquired by the Reporting Person on February 13, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

3. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

Remarks:

	/s/ Maricel Apuli	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BridgeBio Pharma (BBIO) report for Maricel Apuli?

BridgeBio Pharma’s Chief Accounting Officer Maricel Apuli reported an open-market sale of 510 common shares and a separate tax-withholding disposition of 4,349 shares. Both transactions relate to equity compensation activity, including RSU vesting and an earlier employee stock purchase plan acquisition.

How many BridgeBio Pharma (BBIO) shares did Maricel Apuli sell and at what price?

Maricel Apuli sold 510 shares of BridgeBio Pharma common stock in an open-market transaction at $74.31 per share. This sale was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than discretionary market timing.

Why were 4,349 BridgeBio Pharma (BBIO) shares disposed of by Maricel Apuli?

The 4,349 shares were withheld to satisfy Maricel Apuli’s tax obligation related to the vesting of 8,377 RSU-linked common shares. This type of F-code transaction represents tax-withholding, not an open-market sale for investment or portfolio-management purposes.

How many BridgeBio Pharma (BBIO) shares does Maricel Apuli own after these transactions?

Following the reported transactions, Maricel Apuli directly owns 123,945 shares of BridgeBio Pharma common stock. This figure reflects both the open-market sale and the tax-withholding disposition and includes 510 shares previously acquired via the company’s employee stock purchase plan.

What is the significance of the Rule 10b5-1 plan mentioned in the BridgeBio Pharma (BBIO) filing?

The filing states the sale was executed under a Rule 10b5-1 plan adopted on September 8, 2025. Such plans allow insiders to pre-arrange trades, helping separate normal portfolio transactions from potential information-driven trading concerns.

How are employee stock purchase plan shares reflected in BridgeBio Pharma (BBIO) insider holdings?

A footnote explains that Apuli’s holdings include 510 shares acquired on February 13, 2026 through BridgeBio Pharma’s employee stock purchase plan. These ESPP shares are part of the total 123,945 shares reported as directly owned after the disclosed transactions.